Solvay: More clarity on pharma future by Q4

Belgium's Solvay said it should have more clarity on the future of its pharmaceuticals unit in the fourth quarter. All options, including keeping the unit as-is, are still on the table, CEO Christian Jourquin said. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.